Ãëàâíàÿ    Ex Libris    Êíèãè    Æóðíàëû    Ñòàòüè    Ñåðèè    Êàòàëîã    Wanted    Çàãðóçêà    ÕóäËèò    Ñïðàâêà    Ïîèñê ïî èíäåêñàì    Ïîèñê    Ôîðóì   
blank
Àâòîðèçàöèÿ

       
blank
Ïîèñê ïî óêàçàòåëÿì

blank
blank
blank
Êðàñîòà
blank
Nathanson N. (ed.), Ahmed R., Brinton M.A. — Viral Pathogenesis and Immunity
Nathanson N. (ed.), Ahmed R., Brinton M.A. — Viral Pathogenesis and Immunity



Îáñóäèòå êíèãó íà íàó÷íîì ôîðóìå



Íàøëè îïå÷àòêó?
Âûäåëèòå åå ìûøêîé è íàæìèòå Ctrl+Enter


Íàçâàíèå: Viral Pathogenesis and Immunity

Àâòîðû: Nathanson N. (ed.), Ahmed R., Brinton M.A.

Àííîòàöèÿ:

Introductory textbook for graduate students and trainees. Treats all aspects of infection of the animal host with emphasis on mechanisms explaining the complex interaction between parasite and host. Keeps only to the essentials. Softcover. DNLM: Viruses — pathogenicity.


ßçûê: en

Ðóáðèêà: Ìåäèöèíà è çäðàâîîõðàíåíèå/

Ñòàòóñ ïðåäìåòíîãî óêàçàòåëÿ: Ãîòîâ óêàçàòåëü ñ íîìåðàìè ñòðàíèö

ed2k: ed2k stats

Ãîä èçäàíèÿ: 2001

Êîëè÷åñòâî ñòðàíèö: 220

Äîáàâëåíà â êàòàëîã: 01.12.2006

Îïåðàöèè: Ïîëîæèòü íà ïîëêó | Ñêîïèðîâàòü ññûëêó äëÿ ôîðóìà | Ñêîïèðîâàòü ID
blank
Ïðåäìåòíûé óêàçàòåëü
$T_m$      See Mean transit time
Acquired immunodeficiency syndrome (AIDS)      See also Human immunodeficiency virus
Acquired immunodeficiency syndrome (AIDS), murine AIDS features      90
Acquired immunodeficiency syndrome (AIDS), neoplasms      176
Acquired immunodeficiency syndrome (AIDS), opportunistic infections      92 176
Acquired immunodeficiency syndrome (AIDS), susceptibility, AIDS resistance      164—165
Acquired immunodeficiency syndrome (AIDS), susceptibility, HLA-B57 in AIDS susceptibility      165 165t
Adenovirus, apoptosis effects      46 47
Adenovirus, downregulation of major histocompatibility complex class I expression      44—45 87—88
Adenovirus, infection course      148—149
Adenovirus, oncogenesis, E1A role      149—150 149f
Adenovirus, oncogenesis, E1B role      149—150 149f
Adenovirus, oncogenesis, rodent models      149
Adenovirus, oncogenesis, serotype activity      45t
Adenovirus, oncogenesis, tumor suppressor protein inactivation      143
Age, host, virus immunosuppression determinant      94
Age, host, virus susceptibility factors, infancy      165—167
Age, host, virus susceptibility factors, old age      167—168
AIDS      See Acquired immunodeficiency syndrome
ALV      See Avian leukosis virus
Antibody      See Immunoglobulin
Antigen, features      57
Antigen-presenting cell (APC)      See also Dendritic cell function 58
Antigen-presenting cell (APC), vaccination role      189
APC      See Antigen-presenting cell
Apoptosis, adenovirus modulation      46 47
Apoptosis, assays      46
Apoptosis, features      46 47s
Apoptosis, human immunodeficiency virus induction      40 46
Apoptosis, reovirus induction      39—40
Apoptosis, Sindbis virus induction      47
Apoptosis, virus proteins in induction      46—47 47f
ASV      See Avian sarcoma virus
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, host immune response      108
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, neural spread      105—106
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, portal of entry      105
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, target organ      106
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, tissue specificity      107—108
Attenuated virus, comparative pathogenesis of virulent and attenuated viruses, viremia      105
Attenuated virus, selection choice of viruses for virulence studies      104
Attenuated virus, selection cold-adapted variants      103—104
Attenuated virus, selection monoclonal antibody-resistant viruses      104
Attenuated virus, selection mutagenized viruses      104
Attenuated virus, selection temperature-sensitive mutants      103
Attenuated virus, vaccines, efficacy      190—192
Attenuated virus, vaccines, poliovirus vaccine attenuation      9—10 100 193t
Attenuated virus, vaccines, safety      192—193 193t
Attenuated virus, vaccines, tropism      190 192t
Autoimmune disease, molecular mimicry by viruses      78—80
Avian influenza virus, blocking of infection      43f
Avian influenza virus, susceptibility factors      162
Avian influenza virus, tropism variability      35t 36
Avian leukosis virus (ALV), blocking of infection      43f
Avian leukosis virus (ALV), oncogenesis      137—138
Avian leukosis virus (ALV), receptor saturation      42
Avian leukosis virus (ALV), susceptibility factors      162
Avian sarcoma virus (ASV), oncogenesis      137—138
Avian sarcoma virus (ASV), receptor saturation      42
B cell, Epstein — Barr virus infection      150
B cell, immune response overview      48f 57 59f
B cell, immunoglobulin production pathway      58
B cell, kinetics of humoral response      62—63
B cell, maturation      56
B cell, mucosal immune response      67—68
B cell, protection against reinfection      67
B cell, specificity of response      57—58
Bcl-2; apoptosis inhibition      47
Bcl-2; Sindbis virus susceptibility role      166
Bgpl, mouse hepatitis virus susceptibility role      162
Blood, shedding of viruses      22
Bunyavirus, virulence, genetic determinants      107f 109
Burkitt's lymphoma      See Epstein — Barr virus
Canine distemper virus (CDV), immunosuppression induction      90 90f
Carbohydrate, viral receptors      29f
CD4 lymphocyte      See also T cell
CD4 lymphocyte, cell mediated immunopathology effector function      71—72 73
CD4 lymphocyte, cytokine production      65
CD4 lymphocyte, effector functions      65
CD4 lymphocyte, function      58
CD4 lymphocyte, helper cell subsets      58 60
CD4 lymphocyte, human immunodeficiency virus targeting      27—28 44f 83 92—93 93f 121 173—174
CD4 lymphocyte, immunopathology role      75t
CD4 lymphocyte, SU, CD4 binding      171 172f 177
CD4 lymphocyte, virus effects on helper cell balance      60
CD8 lymphocyte      See also T cell assays; 64t
CD8 lymphocyte, cell-mediated immunopathology, clinical disease      73—76
CD8 lymphocyte, cell-mediated immunopathology, experimental examples      72—73
CD8 lymphocyte, cell-mediated immunopathology, mechanisms      70—72
CD8 lymphocyte, cytokine production      71
CD8 lymphocyte, effector functions      65
CD8 lymphocyte, function      58
CD8 lymphocyte, hepatitis B virus clearance      201—202
CD8 lymphocyte, human immunodeficiency virus effects      182 183
CD8 lymphocyte, kinetics of virus response      65—66
CD8 lymphocyte, lymphocytic choriomeningitis virus induction of tolerance      85—86
CD8 lymphocyte, rabies virus response      200
CDV      See Canine distemper virus
Cell cycle, virus regulation      45
Cervical cancer      See Human papillomavirus
Chemokine receptors, CCR5 mutations, AIDS resistance      164—165
Chemokine receptors, CCR5 mutations, human immunodeficiency virus infection resistance      163t 164 182
Chemokine receptors, human immunodeficiency virus utilization, apoptosis induction      46
Chemokine receptors, human immunodeficiency virus utilization, receptor types in binding      171
Chemokine receptors, human immunodeficiency virus utilization, signaling      40
Chemokine receptors, human immunodeficiency virus utilization, strain variations      171
Chemokine receptors, mutations and human immunodeficiency, virus mfection resistance      164 182 183
Chromium-51 release assay, cellular immunity      63f 64
Clearance, virus      18 19
CMV      See Cytomegalovirus
Complement, cascade      57f
Complement, Clq binding by antibodies      62 87
Complement, host defense      55—56
Complement, viral interference of cascade      87
Conjunctiva, virus entry      14
CREB, transcription regulation by viruses      41
Cytomegalovirus (CMV), latency      119—120
Cytomegalovirus (CMV), transcription regulation      41
Cytotoxic T lymphocyte      See CD8 lymphocyte
Dendritic cell, function      56—57 58
Dendritic cell, human immunodeficiency virus infection      173
Dendritic cell, lymphocytic choriomeningitis virus targeting      83—84
Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), antibody-mediated immunopathology      77—78 78f
Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), epidemiology      77—78
Dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS), transmission      77
DHF/DSS      See Dengue hemorrhagic fever/dengue shock syndrome
DNA vaccine, administration      196
DNA vaccine, advantages      196
DNA vaccine, human immunodeficiency virus      207
DNA vaccine, promoters      195
DNA vaccine, protein trafficking      195—196
DNA vaccine, simian immunodeficiency virus      208f
Dulbecco, M.      7
E1A; downregulation of major histocompatibility complex      45
E1A; oncogenesis role      149—150
E1B, oncogenesis role      149—150
E3; trapping of major histocompatibility complex class I molecules      44—45 87—88
E5; oncogenesis role      147
E6; oncogenesis role      147—148
E7; oncogenesis role      147—148
EBNA-1, oncogenesis role      150—151
Ebola virus, necrosis induction      46
EBV      See Epstein — Barr virus
Ectromelia virus, spread in mouse      9f
Ehrlich, Paul      7
ELISA      See Enzyme-linked immunosorbent assay
ELISPOT, antibody assay      61 63
ELISPOT, cellular immunity assay      65
Enzyme-linked immunosorbent assay (ELISA), antibody assay      60
Epithelial cell, polarization and virus infection      17
Epstein — Barr virus (EBV), B cell infection      150
Epstein — Barr virus (EBV), epithelial cell infection      150
Epstein — Barr virus (EBV), infection course      150
Epstein — Barr virus (EBV), latency      119—120 150
Epstein — Barr virus (EBV), oncogenesis      151f
Epstein — Barr virus (EBV), oncogenesis, Burkitt's lymphoma      151—152
Epstein — Barr virus (EBV), oncogenesis, EBNA-1 role      150—151
Epstein — Barr virus (EBV), oncogenesis, genes      152t
Epstein — Barr virus (EBV), oncogenesis, immunosuppression effects      151
Epstein — Barr virus (EBV), oncogenesis, LMP1 role      150—151
Equine infectious anemia virus, persistence mechanisms      122 123t
Exocytosis, virions      38—39
FACS      See Fluorescence-activated cell sorting
Fenner, Frank      7
Finlay, Carlos      6
Fluorescence-activated cell sorting (FACS), cellular immunity assay      64—65
Flv, flavivirus susceptibility role      160—161
Foot-and-mouth disease, history of study      5—6
Fracastoro, Girolamo      3
Fv-1; murine leukemia virus susceptibility role      161—162
Gastrointestinal tract, acid lability of viruses      33
Gastrointestinal tract, entry of viruses      15—16 15t 16f
Gastrointestinal tract, shedding of viruses      21
Glycoprotein viral receptors      27f
HA      See Hemagglutinin
HBV      See Hepatitis B virus
Hemagglutinin (HA), proteolytic activation      32—33 33f
Hemagglutinin (HA), structure      30f
Henle — Koch postulates      5 5s
Heparan, cellular virus receptor      28 29f
Hepatitis A virus, perpetuation      23 23f
Hepatitis B virus (HBV), age effects on susceptibility      167
Hepatitis B virus (HBV), CD8 cell role in clearance      201—202
Hepatitis B virus (HBV), cell-mediated immunopathology      73—76
Hepatitis B virus (HBV), clearance      201 f
Hepatitis B virus (HBV), course of infection      75f 201f
Hepatitis B virus (HBV), cytokines in clearance      65f
Hepatitis B virus (HBV), eradication      24
Hepatitis B virus (HBV), humoral immunity      76
Hepatitis B virus (HBV), immune globulin protection      202 202f 202t
Hepatitis B virus (HBV), mouse model      76s
Hepatitis B virus (HBV), myelin basic protein mimicry      79
Hepatitis B virus (HBV), pathogenesis      200—201 201f
Hepatitis B virus (HBV), persistence      114 117—118
Hepatitis B virus (HBV), vaccination, active immunization of infants      203 203f
Hepatitis B virus (HBV), vaccination, historical perspective      203
Hepatitis B virus (HBV), vaccination, recombinant protein vaccine      194 202
Herpes simplex virus (HSV), cellular receptors      26—27 28
Herpes simplex virus (HSV), complement cascade interference      87 87f 87t
Herpes simplex virus (HSV), Fc receptors as virulence factors      112—113 112f
Herpes simplex virus (HSV), latency      119—120 120f 124—126
Herpes simplex virus (HSV), latency associated transcripts      125
Herpes simplex virus (HSV), life cycle      125f
Herpes simplex virus (HSV), reactivation factors      125—126
Herpes simplex virus (HSV), serotypes      124
HHV-8      See Human herpesvirus 8
Historical perspective, virus research, prospects      11
Historical perspective, virus research; 1900—1950      6—7
Historical perspective, virus research; 1950—1975      7—8
Historical perspective, virus research; 1975 — present      9—11
Historical perspective, virus research; pre-1900s      3—6
HIV      See Human immunodeficiency virus
HPV      See Human papillomavirus
hsv      See Herpes simplex virus
HTLV-I      See Human T-cell lymphotrophic virus type I
Human herpesvirus 8 (HHV-8), cell cycle regulation      45
Human herpesvirus 8 (HHV-8), Kaposi's sarcoma role, discovery      152—153 153t
Human herpesvirus 8 (HHV-8), Kaposi's sarcoma role, pathogenesis      153—154 154f 154t
Human immunodeficiency virus HIV)      See also Acquired immunodeficiency syndrome
Human immunodeficiency virus HIV), acute infection      175—176
Human immunodeficiency virus HIV), apoptosis induction      40 46
Human immunodeficiency virus HIV), blood to tissue spread      20
Human immunodeficiency virus HIV), CD4 cell, counts      175—176
Human immunodeficiency virus HIV), CD4 cell, depletion and immunosuppression      182
Human immunodeficiency virus HIV), CD4 cell, targeting      27—28 44f 83 92—93 93f 121 173—174
Human immunodeficiency virus HIV), CD4 cell, turnover      178—179
Human immunodeficiency virus HIV), CD8 cell effects      182 183
Human immunodeficiency virus HIV), cell cycle regulation      45
Human immunodeficiency virus HIV), cell killing in vitro      173—174
Human immunodeficiency virus HIV), cell killing in vivo      174
Human immunodeficiency virus HIV), cellular immune response      177—178 178f
Human immunodeficiency virus HIV), cellular receptors      172f
Human immunodeficiency virus HIV), cellular receptors, CD4; 26, 26f      28 28f 92 170 171
Human immunodeficiency virus HIV), cellular receptors, chemokine receptors      26f 40 171
Human immunodeficiency virus HIV), cellular receptors, mutations and susceptibility      183t
Human immunodeficiency virus HIV), cellular receptors, saturation      42
Human immunodeficiency virus HIV), clades      182 206
Human immunodeficiency virus HIV), comparative pathogenesis of virulent and attenuated viruses      108
Human immunodeficiency virus HIV), control      183
Human immunodeficiency virus HIV), dendritic cell infection      173
Human immunodeficiency virus HIV), entry      172f
Human immunodeficiency virus HIV), entry, cells      29—30
Human immunodeficiency virus HIV), entry, portal      174
Human immunodeficiency virus HIV), genome      171f
Human immunodeficiency virus HIV), highly-active antiretroviral therapy response      178—179 180f
Human immunodeficiency virus HIV), humoral immune response      177 177f
Human immunodeficiency virus HIV), immunogenic proteins      176—177
Human immunodeficiency virus HIV), immunosuppression mechanisms      92—93 182
Human immunodeficiency virus HIV), kinetics of infection      179f 204f
Human immunodeficiency virus HIV), latency      176
Human immunodeficiency virus HIV), lentivirus features      170—171
Human immunodeficiency virus HIV), molecular mimicry      80t
Human immunodeficiency virus HIV), mutation, evolution during persistent infection      180
Human immunodeficiency virus HIV), mutation, immunological escape mutants      182
Human immunodeficiency virus HIV), mutation, phenotypes      180
Human immunodeficiency virus HIV), mutation, rates      180
Human immunodeficiency virus HIV), Nef downregulation of major histocompatibility complex      44
Human immunodeficiency virus HIV), nonpathogenic infection      180—182
Human immunodeficiency virus HIV), passage      103
Human immunodeficiency virus HIV), perpetuation      23
Human immunodeficiency virus HIV), persistence and turnover      178
Human immunodeficiency virus HIV), phenotype by stage of infection      181f 181t
Human immunodeficiency virus HIV), prospects for study      11
Human immunodeficiency virus HIV), replication      173f
Human immunodeficiency virus HIV), simian immunodeficiency virus chimera, tropism      36—37 36f
Human immunodeficiency virus HIV), simian immunodeficiency virus chimera, vaccination studies      204—206 208f
Human immunodeficiency virus HIV), species susceptibility      171
Human immunodeficiency virus HIV), spread of infection      174
Human immunodeficiency virus HIV), susceptibility, AIDS resistance      164—165
Human immunodeficiency virus HIV), susceptibility, HLA-B57 in AIDS susceptibility      165 165t
Human immunodeficiency virus HIV), susceptibility, infection resistance      164 182 183
Human immunodeficiency virus HIV), transmission      174 183
Human immunodeficiency virus HIV), tropism among isolaes of same virus      108t
Human immunodeficiency virus HIV), vaccination, attenuated virus      203—204
Human immunodeficiency virus HIV), vaccination, cellular immunity induction      206
Human immunodeficiency virus HIV), vaccination, challenges      203—204
Human immunodeficiency virus HIV), vaccination, cross-clade immunity      206—207 207f 207t
Human immunodeficiency virus HIV), vaccination, DNA vaccine      207
Human immunodeficiency virus HIV), vaccination, historical perspective      203—204
Human immunodeficiency virus HIV), vaccination, immunologic correlates of protection      205—206
Human immunodeficiency virus HIV), vaccination, macaque model      204
Human immunodeficiency virus HIV), vaccination, neutralizing antibody induction      206
Human immunodeficiency virus HIV), vaccination, partial immunity protection      204
Human immunodeficiency virus HIV), vaccination, recombinant gp120      203 207
Human immunodeficiency virus HIV), vaccination, viremia and viral set point      174—175 175f 175t 177f 205f
Human papillomavirus (HPV), E2 mimicry of insulin receptor      80t
Human papillomavirus (HPV), genome      145
Human papillomavirus (HPV), oncogenesis, animal models      148 158
Human papillomavirus (HPV), oncogenesis, E5 role      147
Human papillomavirus (HPV), oncogenesis, E6 role      147—148 148f
Human papillomavirus (HPV), oncogenesis, E7 role      147—148 148f
Human papillomavirus (HPV), oncogenesis, immunologic factors      148 148f
Human papillomavirus (HPV), oncogenesis, serotypes      145t
Human papillomavirus (HPV), oncogenesis, transcripts by cancer type      145—146
Human papillomavirus (HPV), oncogenesis, transgenic mouse studies      145t
Human papillomavirus (HPV), oncogenesis, tumor suppressor protein inactivation      143
Human papillomavirus (HPV), receptors      146
Human papillomavirus (HPV), replication      145—147
Human papillomavirus (HPV), serotypes      145t
Human papillomavirus (HPV), transcriptional control of tropism      34 35 35f 146f
Human papillomavirus (HPV), types and virulence      144—145
1 2 3
blank
Ðåêëàìà
blank
blank
HR
@Mail.ru
       © Ýëåêòðîííàÿ áèáëèîòåêà ïîïå÷èòåëüñêîãî ñîâåòà ìåõìàòà ÌÃÓ, 2004-2024
Ýëåêòðîííàÿ áèáëèîòåêà ìåõìàòà ÌÃÓ | Valid HTML 4.01! | Valid CSS! Î ïðîåêòå